KR20220143923A - Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 - Google Patents

Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 Download PDF

Info

Publication number
KR20220143923A
KR20220143923A KR1020227032683A KR20227032683A KR20220143923A KR 20220143923 A KR20220143923 A KR 20220143923A KR 1020227032683 A KR1020227032683 A KR 1020227032683A KR 20227032683 A KR20227032683 A KR 20227032683A KR 20220143923 A KR20220143923 A KR 20220143923A
Authority
KR
South Korea
Prior art keywords
dose
dosage form
administration
optionally
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227032683A
Other languages
English (en)
Korean (ko)
Inventor
존 네스토르
비쟈얀티 크리슈난
Original Assignee
스핏파이어 파마, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스핏파이어 파마, 엘엘씨 filed Critical 스핏파이어 파마, 엘엘씨
Publication of KR20220143923A publication Critical patent/KR20220143923A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020227032683A 2020-02-21 2021-02-21 Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 Pending KR20220143923A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062980093P 2020-02-21 2020-02-21
US62/980,093 2020-02-21
US202063122108P 2020-12-07 2020-12-07
US63/122,108 2020-12-07
US202163133540P 2021-01-04 2021-01-04
US63/133,540 2021-01-04
PCT/US2021/018947 WO2021168386A1 (en) 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use

Publications (1)

Publication Number Publication Date
KR20220143923A true KR20220143923A (ko) 2022-10-25

Family

ID=77391258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032683A Pending KR20220143923A (ko) 2020-02-21 2021-02-21 Glp-1r 및 gcgr 효능제, 제형 및 사용 방법

Country Status (11)

Country Link
US (2) US20210290732A1 (https=)
EP (1) EP4106796A4 (https=)
JP (2) JP7752619B2 (https=)
KR (1) KR20220143923A (https=)
CN (1) CN115427065A (https=)
AU (1) AU2021224246A1 (https=)
BR (1) BR112022016470A2 (https=)
CA (1) CA3168001A1 (https=)
IL (1) IL295744A (https=)
MX (1) MX2022010320A (https=)
WO (1) WO2021168386A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
MX360816B (es) * 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
US20230317230A1 (en) * 2019-05-02 2023-10-05 Closed Loop Medicine Ltd. Method for treating obesity
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
CN118234742A (zh) * 2021-12-01 2024-06-21 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
JP2025537192A (ja) * 2022-11-05 2025-11-14 スピットファイア ファーマ エルエルシー Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513384A (ja) * 2004-09-17 2008-05-01 ノボ ノルディスク アクティーゼルスカブ インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
MX2007005521A (es) * 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
CN108892709A (zh) * 2011-05-18 2018-11-27 欧莫德里斯制药公司 改良的肽药物
MX360816B (es) * 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
ES2906975T3 (es) * 2012-11-20 2022-04-21 Eumederis Pharmaceuticals Inc Productos farmacéuticos de péptidos mejorados
EP2986313B1 (en) * 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PT3155017T (pt) * 2014-05-28 2024-05-14 Mederis Diabetes Llc Farmacêuticos peptídicos melhorados para resistência à insulina
JP2017517549A (ja) * 2014-06-13 2017-06-29 サノフイ 活性薬剤成分のナノカプセル製剤
PE20170471A1 (es) * 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
AU2015320545C1 (en) * 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP4523705A3 (en) * 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
EP4506017A3 (en) * 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders

Also Published As

Publication number Publication date
AU2021224246A1 (en) 2022-09-15
US20210290732A1 (en) 2021-09-23
JP2026021305A (ja) 2026-02-10
CN115427065A (zh) 2022-12-02
EP4106796A4 (en) 2024-04-17
US20250262280A1 (en) 2025-08-21
EP4106796A1 (en) 2022-12-28
IL295744A (en) 2022-10-01
BR112022016470A2 (pt) 2022-11-22
JP2023514992A (ja) 2023-04-12
CA3168001A1 (en) 2021-08-26
JP7752619B2 (ja) 2025-10-10
MX2022010320A (es) 2023-01-30
WO2021168386A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US12257229B2 (en) Peptide pharmaceuticals for treatment of NASH and other disorders
US20250262280A1 (en) GLP-1R and GCGR Agonists, Formulations, and Methods of Use
US20250134963A1 (en) Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists
US20240148879A1 (en) Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
US20240269238A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist
US12171806B2 (en) Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
US20240277815A1 (en) Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist
EP4611792A1 (en) Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
HK40101792A (zh) 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902